US FDA clears multi-cancer blood test but Hong Kong doctors seek more data

US regulators approved a blood test detecting multiple cancers early, but Hong Kong medical institutions say more data is needed before widespread use.

The US FDA panel granted premarket approval for Grail’s Galleri test on September 24, 2026. This multi-cancer early detection blood test analyzes circulating tumor DNA in asymptomatic individuals. Hong Kong medical institutions report doctors remain cautious about clinical utility, stating more data is required before wider adoption. Institutions are actively exploring ways to broaden the test’s use, though adoption faces challenges despite growing interest in the technology. The test’s potential to catch cancers before symptoms arise could reduce global healthcare costs and save lives. However, real-world impact depends on Hong Kong’s ability to gather sufficient evidence through clinical trials before implementation.

Source: SCMP Tech